News | News By Subject | News by Disease News By Date | Search News

Genital warts News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
FDA Approves Zyclara(R) (imiquimod) Cream, 3.75% for the Treatment of External Genital Warts     3/25/2011
Bradley Pharmaceuticals (BDY) Announces Polyphenon E(R) Ointment, 15% Approved By FDA     11/1/2006
Novartis Corporation (NVS) And TAP Pharmaceutical Products Inc. To Co-Promote Genital Herpes Drug     9/29/2006
Merck & Co., Inc. (MRK) Cervical Cancer Vaccine Wins Backing From U.S. Advisers     5/19/2006
Merck & Co., Inc. (MRK) Cervical Cancer Vaccine Prevents Lesions In Phase III Trial; Shares On The Climb     10/6/2005
Flamel Technologies (FLML) Announces Termination Of Licensing Agreement With Biovail Laboratories Inc. For Genvir And Recovery Of Rights     3/4/2005
MediGene AG (DX:MDG) Halts Trials In Vaccine Partnered With Aventis S.A. (AVE)     8/4/2004

News from Around the Web

Press Releases
MediGene AG (MDGEF.PK) And Kora Healthcare Sign Agreement For The Commercialisation Of Veregen® In United Kingdom And Ireland     4/8/2014
Moberg Derma Initiates Phase II Trial With Limtop Following Positive Phase I Results     5/2/2012
MediGene AG (MDGEF.PK) Announces Approval of Veregen(R) in Spain     3/30/2011
Centers for Disease Control and Prevention (CDC) Recommends Nycomed's VEREGEN(R) as Therapeutic Option for External Genital Warts in the 2010 Sexually Transmitted Diseases Treatment Guidelines     1/5/2011
Graceway Pharmaceuticals, LLC Release: New Data Demonstrate Zyclara(TM) Imiquimod 3.75% Superior to Placebo for Treatment of External Genital Warts (EGW)     7/9/2010
Sanofi Pasteur MSD Release: Sustained High Efficacy of Gardasil(R) Against Early Cervical Lesions, Precancerous Vulvar and Vaginal Lesions, and Genital Warts in Longest Follow-up of Large Phase III Studies     3/7/2008
Onset Therapeutics Announces FDA Submission for Novel Product for Topical Treatment of Genital Warts     12/6/2007
Hemispherx Biopharma (HEB) and Armada Health Care Enter Agreement to Launch Alferon N Injection(R) via Specialty Pharmacy Network     4/23/2007
Starpharma Holdings Ltd Release: U.S. Clinical Trial Of VivaGel(TM) For Genital Herpes Commences     10/24/2006
Starpharma Holdings Ltd Release: National Institutes of Health (NIH) Funds Clinical Development Of VivaGel(TM) For Genital Herpes     4/20/2006
MediGene AG (DX:MDG) And Bradley Pharmaceuticals (BDY) Enter Marketing And Development Partnership For Polyphenon(R) E Ointment     1/31/2006
MediGene AG (DX:MDG) Announces FDA Acceptance Of New Drug Application For Polyphenon(R) E* Ointment For The Treatment Of Genital Warts     12/1/2005
MediGene AG (DX:MDG) Submits New Drug Application For Polyphenon(R) E Ointment For The Treatment Of Genital Warts     9/30/2005
MediGene AG (DX:MDG) Successfully Completes Pivotal Clinical Phase III Trials Of Polyphenon® E Ointment For The Treatment Of Genital Warts     12/9/2004
Stressgen Biotechnologies Corporation (SSB.TO) Completes Enrollment In HspE7 Internal Genital Warts Trial     12/2/2004